Lupin Ltd Q1 FY2025 Concall Summary

Key Takeaways

• Strong quarter, broad-based beat: Revenue grew double digits YoY and QoQ, with EBITDA margins reaching 23.3%, driven by US respiratory products, new launches, and India outperformance.
• US business structurally improved: Margins returned to strong levels on complex generics and operational efficiencies, while a more rational pricing environment and drug shortages reduced gross-to-net leakage.
• FY26 shaping up as a breakout year: Tolvaptan 180-day exclusivity, Liraglutide, and Risperdal Consta® are not in current guidance, creating a visible pipeline of large, uncounted upside.
• India franchise widening its moat: Prescription business grew 10.5%, well ahead of the 8.7% IPM, with in-house diabetes portfolio growing at 2x the category and a trade generics carve-out now complete for sharper focus.
• What to watch next quarter: Pred Forte® CGT launch ramp, the Mirabegron 50 mg at-risk decision, Slynd® hearing outcome in August, and whether R&D spend steps up as guided toward the INR 1,800 crore full-year target.

US Business: The Turnaround Is Now Delivering

• Growth drivers: Respiratory franchise (Tiotropium, Albuterol) contributed strongly, while new launches Mirabegron and Doxycycline more than offset erosion on products like Suprep® that faced additional competition.
• Spiriva® share dynamics: Share holds at ~30%, consistent with past respiratory generics. The brand's \$35 copay shifted volume toward the Commercial segment where Lupin has higher share; low Medicare/Medicaid share provides room for gains.
• Albuterol stability: Market share stable at 20% with no material customer losses. Flu-season demand affected supply phasing but not share; management assumes some erosion when Amphastar launches.
• Price erosion rationalizing: Mid-single digit erosion persists, but industry structure has changed: companies exited unprofitable products, drug shortages hit a decade high, and customers grew concerned about economic viability, producing a more rational generic market.
• Gross-to-net discipline: Working capital management, failure-to-supply penalties, back orders, and returns management have improved significantly over recent quarters, limiting leakage. No material channel shift from new entrants like Mark Cuban or Amazon.
• US margins: Not broken out region-wide but described as "above the company average," reflecting the shift to complex generics and productivity focus.

Vinita Gupta: "So, our customers have been very concerned as well about product exits and the economic viability of the generic business for the generic manufacturers. And as a result, we have seen more rational generic market."

The FY26 Pipeline: Visible, Large, and Uncounted

• Tolvaptan: "Very certain launch" in Q1 FY26 with 180-day exclusivity, won on both litigation and product approval. Not counted in current guidance.
• Liraglutide (Victoza®/Saxenda®): Filed; based on the CRL, launch expected next fiscal year. Management expects a staggered launch given manufacturing difficulty, producing a more rational market than a simultaneous entry.
• Risperdal Consta®: Recent successful inspection at the Nanomi site; launch hoped for next fiscal year subject to FDA approval. Other long-acting injectables on a 505(b)(2) platform are in early-stage development.
• Dulera®: Pending CRL; response expected this fiscal year, with potential launch next fiscal year or FY27.
• Respimat® and Ellipta®: Exhibit batches planned this fiscal year; filing targeted for early FY26. These represent the largest R&D investment area within complex generics.

Vinita Gupta: "the 180-day exclusive window itself for such a large product is a great opportunity for fiscal year '26."

Near-Term Launches and Litigation Catalysts

• Pred Forte®: CGT approval received last week; six-month exclusivity expected if Lupin reaches market before any other applicant. Inventory build underway for imminent launch.
• Mirabegron 50 mg: Evaluating launch timing and monitoring the upcoming hearing on the '780 patent; will evaluate launching at risk. Exclusivity duration depends on litigation outcome: if a typical brand-generic settlement, additional competition expected at the end of the 30-month stay around September next year, but could extend beyond six months.
• Slynd®: Hearing set for the last week of August; preparing for launch in case of a win.
• Doxil®: Launching in the next couple of weeks.
• Glucagon: Expected later this fiscal year based on filing status.
• Ophthalmic portfolio: Pred Forte® plus two or three other ophthalmic products launching in Q3; Pred Forte® is the largest.
• AmBisome® dropped: Based on competitive intensity and number of approved players, management decided not to invest further in development.

India and Emerging Markets: Outperformance with Structural Tailwinds

• India prescription business: Grew 10.5% vs IPM growth of 8.7%, 21% ahead of market. Cardiac, Respiratory, GI, and Vitamins grew well ahead of market. In-house diabetes portfolio grew at 2x category growth.
• Volume story: Rx volume growth of 5% was much higher than industry growth of 0.91%, driven by the non-in-license portfolio.
• Trade generics carve-out: Completed the transfer to a 100% owned subsidiary for agility, better focus, and growth.
• In-license diabetes dynamics: One patent expiry coming at the end of Q4; the portfolio currently grows at ~3%. After loss of exclusivity, market share and pricing come down but margin profile improves substantially: volumes surge on price reduction, and within 2–3 years profitability exceeds the original level.
• Emerging markets: Double-digit growth driven by Mexico (facility cleared October 2023, now ramping into ophthalmic and private segment), Philippines (branded generics, new products, commercial excellence), and South Africa.
• Other developed markets: Strong double-digit growth from Canada (Zaxine®, Spiriva®, Etanercept), UK (Luforbec®), and new product launches in Germany and Australia.
• MR expansion: Plan to add a couple of hundred representatives this year.

Vinita Gupta: "We are confident that our reach through our 10,000 plus reps along with our portfolio enhancements will enable us to grow around 20% to 30% higher than the market in the year ahead as we have guided in our earlier interactions."

Margins, R&D, and Capital Allocation

• Gross margin: 68.4%, up on better product mix, lower in-licensed product sales, increased volumes, and cost improvements. A 0.9% inventory blip lowered margins slightly; management calls the level sustainable barring geopolitical shocks.
• EBITDA margin: 23.3%, driven by higher gross margins, operating leverage, and lower R&D spend in the quarter. Adjacencies (biosimilars, etc.) drag margins by 1.5–2 percentage points.
• R&D trajectory: Q1 was light; spend expected to step up from Q2 onward toward the INR 1,800 crore full-year target. ~60% of investment goes to inhalation and injectables, with some in biosimilars and the rest in oral solids.
• Capital deployment: Open to acquisitions if the proposition is compelling; priority areas are India (small bolt-on generics) and specialty. Debt guardrail: total debt should be about twice EBITDA. Currently debt-free.
• ETR: Full year expected around 20%.

Ramesh Swaminathan: "Barring any unforeseen situations like geopolitical tensions in the Middle East and the like, we feel confident of maintaining gross margins around these levels going ahead."

Biosimilars and Complex Generics Strategy

• Biosimilar lessons: Adalimumab saw intense competition and the brand held on long; Lupin is "really glad" it did not participate. Biosimilars proved difficult given high investment and access challenges. Ranibizumab (Lucentis®) is a niche, smaller product with streamlined market access; Phase III trial successful, filing to follow.
• Etanercept: Launched in Canada; Australia launch hoped for soon. US opportunity is "a little bit away," with patent expiry in CY29.
• Pegfilgrastim: Filing processed; observations at the biotech facility have been remediated and the application resubmitted; optimistic on clearing the facility from a compliance perspective.
• Respiratory complex generics: Majority of R&D focus; largest increase on Respimat®, Ellipta®, and the Dulera® CRL response.

Vinita Gupta: "One, we are really glad that we didn't have Adalimumab, because the number of competitors, the competitive intensity there was really, really high."

Guidance & Commitments

Key Metrics